Related references
Note: Only part of the references are listed.A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)
Kenneth C. Kalunian et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects
Alexis Mathian et al.
DRUGS (2015)
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody
Li Peng et al.
MABS (2015)
Targeting of type I interferon in systemic autoimmune diseases
Mary K. Crow et al.
TRANSLATIONAL RESEARCH (2015)
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R. A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Advances in understanding the role of type I interferons in systemic lupus erythematosus
Mary K. Crow
CURRENT OPINION IN RHEUMATOLOGY (2014)
Type I Interferon in the Pathogenesis of Lupus
Mary K. Crow
JOURNAL OF IMMUNOLOGY (2014)
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
Bernard R. Lauwerys et al.
RHEUMATOLOGY (2014)
Overall and Cause-Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta-Analysis of Observational Studies
Marko Yurkovich et al.
ARTHRITIS CARE & RESEARCH (2014)
Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
Avram Goldberg et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Regulation of type I interferon responses
Lionel B. Ivashkiv et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti-Interferon-α Receptor Antibody
B. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
The economic burden of systemic lupus erythematosus
Pantelis Panopalis et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2012)
Emerging therapies for systemic lupus erythematosus - Focus on targeting interferon-alpha
Eben I. Lichtman et al.
CLINICAL IMMUNOLOGY (2012)
Glucocorticoid use and abuse in SLE
Guillermo Ruiz-Irastorza et al.
RHEUMATOLOGY (2012)
Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus
Rachel Klein et al.
ARCHIVES OF DERMATOLOGY (2011)
The type I interferon system in the development of lupus
Lars Ronnblom et al.
SEMINARS IN IMMUNOLOGY (2011)
Numerical scoring for the BILAG-2004 index
Chee-Seng Yee et al.
RHEUMATOLOGY (2010)
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN alpha antibody, in systemic lupus erythematosus
Yihong Yao et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Building a Measure of Fatigue: The Functional Assessment of Chronic Illness Therapy Fatigue Scale
Eleanor Smith et al.
PM&R (2010)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Mortality in systemic lupus erythematosus
S. Bernatsky et al.
ARTHRITIS AND RHEUMATISM (2006)
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus
J Albrecht et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
DA Isenberg et al.
RHEUMATOLOGY (2005)
Share Paper
